Dr. Ferrari was born in Padova, Italy in 1959. He is married to Paola Del Zotto Ferrari. They have five children: Giacomo (age 22); Kim and Chiara (twins, age 20), and Ilaria and Federica (twins, age 13). Dr. Ferrari is a citizen of the USA.
Dr. Ferrari serves as President and CEO of The Methodist Hospital Research Institute, where he holds the Ernest Cockrell Jr. Distinguished Endowed Chair. He is also Professor of Internal Medicine at the Weill Cornell Medical College, Adjunct Professor of Experimental Therapeutics The University of Texas M.D. Anderson Cancer Center, Professor of Bioengineering at Rice University, Adjunct Professor of Biomedical Engineering at UT Austin, and President of The Alliance for NanoHealth in Houston.
Dr. Mauro Ferrari is a founder of biomedical nano/micro-technology, especially in their applications to drug delivery, cell transplantation, implantable bioreactors, and other innovative therapeutic modalities. In these fields, he has published more than 200 peer-reviewed journal articles and 6 books. He is the inventor of more than 30 issued patents, with about thirty more pending in the US and internationally. His contributions have been recognized by a variety of accolades, including: the Presidential Young Investigator Award of the National Science Foundation; the Shannon Director's Award of the National Institutes of Health; the Wallace H. Coulter Award for Biomedical Innovation and Entrepreneurship; and the Italiani nel Mondo Award from the Italian Ministry of Foreign Affairs. His career research and development portfolio totals over $50 million, including support from the NCI, NIH, DoD, NASA, NSF, DARPA, DoE, the State of Texas, and the State of Ohio, The Ohio State University, and several private enterprises. He began his academic career at the University of California, Berkeley, where he tenured in Material Science, Civil Engineering, and Bioengineering. Upon recruitment to the Ohio State University, he served as the Edgar Hendrickson Professor of Biomedical Engineering, Professor of Internal Medicine, Mechanical Engineering, Materials Science and Associate Vice President, Health Sciences Technology and Commercialization, Associate Director of the Dorothy M. Davis Heart and Lung Research Institute and Director of the Biomedical Engineering Center. Upon recruitment to Houston, he served as Professor and Chair of the Department of Nanomedicine at the University of Texas Health Science Center.
Dr. Ferrari also served as Special Expert on Nanotechnology at the National Cancer Institute in 2003-2005, providing leadership into the formulation, refinement, and approval of the NCI's Alliance for Nanotechnology in Cancer, currently the world's largest program in medical nanotechnology.
Dr. Ferrari’s degrees are in Mathematics (Padova, 1985, Italy), and Mechanical Engineering (U.C. Berkeley, M.S. 1987, & Ph.D. 1989). He attended medical school at the Ohio State University (2002-03).
Dr. Ferrari is an academic- entrepreneur, with several companies that originated from his laboratory. He currently serves on the Board of Director three companies: Nanomedical Systems of Austin TX; Leonardo Biosystems of Houston TX, and NASDAQ-traded Arrowhead Research Corporation (NASDAQ:ARWR).